Rogers R, Ehmann S, Tew WP, Broach V. Isolated splenic high-grade serous carcinoma: A case report.
Gynecol Oncol Rep 2021;
37:100818. [PMID:
34258358 PMCID:
PMC8253960 DOI:
10.1016/j.gore.2021.100818]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 06/08/2021] [Accepted: 06/20/2021] [Indexed: 11/21/2022] Open
Abstract
We present a unique case of high-grade serous carcinoma isolated to the spleen at the time of diagnosis.
This isolated splenic high-grade serous carcinoma was confirmed by radiologic, clinical, and pathologic assessment.
A multigene tumor panel test revealed somatic PALB2 and ARID1 mutations and a TP53 hotspot mutation.
We present a unique case of high-grade serous carcinoma isolated to the spleen at the time of diagnosis, without any tumor present in the ovary, fallopian tubes, omentum or uterus, which was pathologically consistent with metastatic Mullerian carcinoma. Tumor sequencing with the MSK-IMPACT (Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets) multigene tumor panel test was performed, which revealed somatic mutations in PALB2 and in ARID1, as well as a TP53 hotspot mutation.
Collapse